Aged
Conditions
Interventions
There will be 5 face-to-face meetings, every 14 days, with tests validated in Brazil or semi-structured (based on the literature), with 60 patients in all.
Metting 1: a) Brief explanation of clonazep
c) medical anamnesis
d) Delivery of the Sleep Hygiene and Cartilage Primer Gradual reduction of clonazepam, both validated (by the Delphi technique) by the Clinical Pharmacy League of the Federal University of São João de
III-Pittsburg Sleep Quality Index -BR
Decrease of 25% of the daily dose of clonazepam, taking 75% of the initial dose of clonazepam.
Metting 2:
I-PSQI-BR
II-Signs and symptoms based on literature
III
II-Signs and symptoms based on literature
III-Sociodemographic and clinical questionnaire, semi-structured
Decrease of 25% of the daily dose of clonazepam, taking 25% of the initial dose of clonazepam.
Meeting 4:
I-PSQI-BR
II-Signs and symptoms based on literature
Clonazepam dose stop.
Meeting 5 (final evaluation)
I - WHOQOL-BREF
II - Instrument for the evaluation of falls validated in Brazil (IAQI)
III-Pittsburg Sleep Quality Index -BR
IV- Medical anamese.
Addendum: a) Psychologists from the Health Units of the study will be at the disposal of patients in discretion, as well as the study pharmacy.
b) In case of signs and symptoms o
Sponsors
Universidade Federal de São João del-Rei (UFSJ)
Universidade Federal de São João del-Rei (UFSJ)
Eligibility
Age
60 Years to 100 Years
Inclusion criteria
Inclusion criteria: Elderly patients in clinical use of clonazepam will be included for anxiety and insomnia; administered daily for at least three months; which were attended at the Basic Health Units in question.
Exclusion criteria
Exclusion criteria: Epileptic patients will be excluded; patients in psychiatric treatment and / or with a history of psychosis; patients dependent on alcohol and illicit drugs; patients who are not cognitively competent and do not have a caregiver, according to the mini mental state examination; other unforeseen situations will be analyzed, in an individualized way, by the doctor of the health unit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is to assess the proportion of elderly people who were able to reduce the dose of clonazepam or the total withdrawal of the drug as measured by the Clonazepam Deprescription Protocol in the elderly | — |
Secondary
| Measure | Time frame |
|---|---|
| To identify abstinence symptoms of clonazepam, as measured by the Benzodiazepine withdrawal symptom questionnaire;To verify if there was a change in quality of life before and after the depression, evaluated through the World Health Organization Quality of Life Group (WHOQOL-bref) | — |
Countries
Brazil
Contacts
Public ContactComitê de Ética em Pesquisa cepes_cco_dona_lindu
Universidade Federal de São João del-Rei (UFSJ)
Outcome results
None listed